GenMont Biotech (Taiwan) Performance
| 3164 Stock | TWD 20.05 0.10 0.50% |
The company retains a Market Volatility (i.e., Beta) of -0.0333, which attests to not very significant fluctuations relative to the market. As returns on the market increase, returns on owning GenMont Biotech are expected to decrease at a much lower rate. During the bear market, GenMont Biotech is likely to outperform the market. At this point, GenMont Biotech has a negative expected return of -0.26%. Please make sure to check out GenMont Biotech's total risk alpha, maximum drawdown, and the relationship between the jensen alpha and treynor ratio , to decide if GenMont Biotech performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days GenMont Biotech has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of abnormal performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in December 2024. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors. ...more
| Begin Period Cash Flow | 274.8 M | |
| Total Cashflows From Investing Activities | -153.1 M |
GenMont |
GenMont Biotech Relative Risk vs. Return Landscape
If you would invest 2,375 in GenMont Biotech on August 25, 2024 and sell it today you would lose (370.00) from holding GenMont Biotech or give up 15.58% of portfolio value over 90 days. GenMont Biotech is generating negative expected returns and assumes 0.8676% volatility on return distribution over the 90 days horizon. Simply put, 7% of stocks are less volatile than GenMont, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
GenMont Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for GenMont Biotech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as GenMont Biotech, and traders can use it to determine the average amount a GenMont Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.3003
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 3164 |
Estimated Market Risk
| 0.87 actual daily | 7 93% of assets are more volatile |
Expected Return
| -0.26 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.3 actual daily | 0 Most of other assets perform better |
Based on monthly moving average GenMont Biotech is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of GenMont Biotech by adding GenMont Biotech to a well-diversified portfolio.
GenMont Biotech Fundamentals Growth
GenMont Stock prices reflect investors' perceptions of the future prospects and financial health of GenMont Biotech, and GenMont Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on GenMont Stock performance.
| Return On Equity | 0.0535 | |||
| Return On Asset | 0.0289 | |||
| Profit Margin | 0.23 % | |||
| Operating Margin | 0.20 % | |||
| Current Valuation | 1.76 B | |||
| Shares Outstanding | 86.37 M | |||
| Price To Earning | 12.36 X | |||
| Price To Book | 1.58 X | |||
| Price To Sales | 5.47 X | |||
| Revenue | 427.93 M | |||
| EBITDA | 161.32 M | |||
| Cash And Equivalents | 999.04 M | |||
| Cash Per Share | 11.24 X | |||
| Total Debt | 34.08 M | |||
| Debt To Equity | 2.10 % | |||
| Book Value Per Share | 15.62 X | |||
| Cash Flow From Operations | 111.66 M | |||
| Earnings Per Share | 1.01 X | |||
| Total Asset | 1.7 B | |||
About GenMont Biotech Performance
Evaluating GenMont Biotech's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if GenMont Biotech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if GenMont Biotech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
GenMont Biotech Incorporation engages in the research, development, and production of functional probiotics in Taiwan. The company was founded in 2000 and is based in Tainan, Taiwan. GENMONT BIOTECH operates under Biotechnology classification in Taiwan and is traded on Taiwan Stock Exchange.Things to note about GenMont Biotech performance evaluation
Checking the ongoing alerts about GenMont Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for GenMont Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| GenMont Biotech generated a negative expected return over the last 90 days | |
| About 37.0% of the company shares are owned by insiders or employees |
- Analyzing GenMont Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether GenMont Biotech's stock is overvalued or undervalued compared to its peers.
- Examining GenMont Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating GenMont Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of GenMont Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of GenMont Biotech's stock. These opinions can provide insight into GenMont Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for GenMont Stock Analysis
When running GenMont Biotech's price analysis, check to measure GenMont Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GenMont Biotech is operating at the current time. Most of GenMont Biotech's value examination focuses on studying past and present price action to predict the probability of GenMont Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GenMont Biotech's price. Additionally, you may evaluate how the addition of GenMont Biotech to your portfolios can decrease your overall portfolio volatility.